# Lead Development & Optimization Shared Resource

> **NIH NIH P30** · UNIVERSITY OF KANSAS MEDICAL CENTER · 2024 · $121,746

## Abstract

LEAD DEVELOPMENT AND OPTIMIZATION SHARED RESOURCE (LDOSR): ABSTRACT
The Lead Development and Optimization Shared Resource (LDOSR) is a shared resource of The University of
Kansas Cancer Center (KUCC), composed of three component laboratories located on the KU Lawrence West
Campus: High-Throughput Screening (HTS), Medicinal Chemistry (MDCM) and the Biopharmaceutical
Innovation and Optimization Center (BIOC). LDOSR provides preferred access to KUCC members to
accelerate projects from drug-target discovery through high-throughput screening, compound hit prioritization,
secondary in vitro confirmatory assays, medical chemistry optimization, in vitro pharmacology testing, in vivo
pharmacokinetics, and drug delivery formulations for in vivo preclinical proof-of-concept testing. The activities
involved with the generation, evaluation, and optimization of drug candidates is an iterative process that
crosses several scientific disciplines. The LDOSR has been structured to optimize services under a single,
easy-to-access umbrella, with oversight from the Director and a team of project managers, allowing projects to
move seamlessly between component laboratories. Comprehensive plans tailored to fit each project’s needs
ensure users get the most relevant data to move their projects forward. Additionally, the LDOSR offers drop-in
ready grant submission and publication language. Over the past five years (2016-2020), the LDOSR has
supported 167 KUCC member projects (~76% were peer-review funded). The LDOSR leverages research
infrastructure established, historically, through internationally recognized medicinal and pharmaceutical
chemistry research conducted by the University of Kansas School of Pharmacy. Added to this is the availability
of industry experienced scientists from former area Pharma and CRO companies. The LDOSR has
successfully recruited top-notch scientists with industry and academic qualifications to lead and staff the three
component laboratories. The LDOSR, working with the Associate Director for Translational Research,
established the Drug Discovery and Development Steering Committee. This translational-research catalyst
provides a forum for KUCC investigators to develop research concepts at the chemistry/biology interface with
support from the LDO laboratories. The LDOSR partners with The Institute for Advancing Medical Innovation to
advance drug discovery projects through early drug development, actively conducting and supporting studies
necessary to enable first-in-human clinical trials. Additionally, LDOSR staff serve on the Investigator-Initiated
Trial Steering Committee, which facilitates evaluation of development candidates in early phase experimental
therapeutics trials conducted by the D3ET research program. Lastly, bioanalytical methods for determination of
drug and metabolite concentrations in preclinical matrices, are transferred to the Clinical Pharmacology Shared
Resource where they are cross-validated in human matrices under GLP...

## Key facts

- **NIH application ID:** 10906357
- **Project number:** 5P30CA168524-13
- **Recipient organization:** UNIVERSITY OF KANSAS MEDICAL CENTER
- **Principal Investigator:** Scott James Weir
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $121,746
- **Award type:** 5
- **Project period:** 2012-07-11 → 2027-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10906357

## Citation

> US National Institutes of Health, RePORTER application 10906357, Lead Development & Optimization Shared Resource (5P30CA168524-13). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/10906357. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*